04.02.2019 Issue 445

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Xarelto Ad with List Price Airs

Monday, April 1

Johnson & Johnson's new television ad for its blood thinner Xarelto hit the air March 29, becoming the first direct-to-consumer ad in the U.S. to feature the drug's list price, MM&M reports.

Speakers Talk Drug Coupons at AMCP

IQVIA’s Long Talks Health Care Trends

AMCP 2019 Session Spotlights Disruptors, Innovators

Report: Trump, Pelosi in Talks on Legislation to Reduce Drug Prices

Ali Talks CAR-T Outcomes-Based Contracts

Cothran, Knoth Say Trust is Key in VBCs

LaMattina: Outcomes-Based Pricing Not Cure-All for High Prices


Senior Medical Writer

Senior Research Analyst (HEOR)

Scientific Writer

Medical Statistician

Industry Spotlight


Conferences Webinars
The HealthTech Summit USA 2019
    April 4, Philadelphia, Pennsylvania

Decision Analytic Modelling for Economic Evaluation
    April 8-9, York, England

Copay Accumulator Programs Summit West
    April 9, San Francisco, California

Formulary, Co-Pay and Access Summit
    April 9-11, San Francisco, California

The Use of MCDA for HTA Agencies – Options, Limitations, and the Way Forward
    April 3

MCDA - How to Guide Through the Application of Different Methods for Assessment and Prioritization of Rare Disease Health Technologies
    April 4

Big Data, RWD and RWE: What’s the Difference and How is it Changing the Research Landscape?
    April 15


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
             Truven    
              Evidera    HealthCore    University of FL
Xcenda    OM1    Parexel    Jefferson     Dymaxium
Precision Xtract    Pharmerit    eMax Health    Sciformix
Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn